About Timber Pharmaceuticals

Timber Pharmaceuticals was founded in 2019 to develop treatments for unmet needs in medical dermatology. We have a particular focus on rare diseases or conditions of the skin for which there are no current treatments. Rare skin diseases are among the most neglected therapeutic areas in the pharmaceutical industry. Over 450 different rare skin diseases have been identified, and yet there have been only 17 FDA Approvals for eight different rare dermatological conditions since the Orphan Drug Act was passed in 1983.

 

Timber was formed around the collaboration of three companies with demonstrated experience in all phases of drug development and clinical research. Our team includes world class advisors and a strong leadership team with a proven track record of success in advancing therapies to treat both rare diseases and dermatologic diseases and conditions.

 

We are initially targeting multiple indications in rare/orphan dermatology with no approved treatments. Our investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles.